FinBoss.io
CSEN
  • Crypto prices
  • Liquidation War
  • Crypto tools
  • Bitcoin on-chain
  • US macro
  • US stocks
    • Largest US stocks
    • Stock screener
    • Earnings calendar
    • Insider trading
    • Market heatmap
  • Markets
  • Tools
  • Guides
  • FinBot
FinBoss.io
Crypto prices
Liquidation War
Crypto tools
Altcoin Season Index
Big players (on-chain)
Bitcoin halving countdown
Bear market radar
Bitcoin on-chain
Hashrate
Mining difficulty
Mining pools
Mempool and fees
On-chain activity
MVRV and NUPL
SOPR
Holders
Supply in profit
Rainbow Chart
Fair value
Pi Cycle Top
US macro
FedWatch
Interest rates
Treasury yields
Inflation
Liquidity and Bitcoin
Business cycle
US stocks
Largest US stocks
Stock screener
Earnings calendar
Insider trading
Market heatmap
Markets
Stock indices
Commodities
Forex rates
Bear market radar
Famous investors' portfolios
Tools
Dashboards
Investor dashboardTrader dashboardBeginner dashboard
Calculators
Compound interestDCA calculatorDrawdown recovery
Compare
BrokersCrypto exchanges
Přehled sekce Tools →
Guides
FinBot
CSEN
Home
Stocks
Tenet Healthcare Corp
TH

Tenet Healthcare Corp

THCNASDAQ

Stock · Data from SEC EDGAR 13F · Held by 13 of 87 tracked investors

$262.05
▼ 2.57%
Famous investorshold 13buying 0selling 0
Price (USD)
$262.05
Market cap
$21.1B
P/E ratio
10.1
Tracked investors holding
13 of 87
Next earnings
29 Oct 2026

Tenet Healthcare Corp at a glance

An overview of the financial statements, in plain language. Switch to the advanced view for charts.

FinBoss score
73out of 100
  • Valuation95
  • Growth52
  • Profitability68
  • Quality85
  • Debt54
  • Stability85
In its favour
  • It earns 37 USD a year on every 100 USD of invested capital (ROE).

Earnings results

QuarterReportedEPSAnalyst estimateSurprise
Jun 202623 Jul 20266.124.08+50%
Mar 202630 Apr 20264.824.21+14.5%
Dec 202511 Feb 20264.704.08+15.2%
Sep 202528 Oct 20253.703.33+11.1%

EPS is earnings per share. The surprise is the difference against the analysts' consensus. Source: Nasdaq, in dollars.

Chart THC

Insider purchases

last 90 days, SEC Form 4
Loading insider trades…

Which investors hold this stock

13
LR
Larry Robbins
Glenview Capital
7.62%$418,248,395▲ +46.6%
DE
David Einhorn
Greenlight Capital
4.86%$99,447,853▲ +44.3%
LB
Louis Bacon
Moore Capital Management
0.33%$22,018,006New position
JG
Joel Greenblatt
Gotham Asset Management
0.08%$32,637,603▲ +20.2%
CA
Cliff Asness
AQR Capital Management
0.07%$198,266,419▼ -26%
KG
Ken Griffin
Citadel Advisors
0.04%$330,307,700▲ +321.6%
SC
Steven Cohen
Point72 Asset Management
0.04%$34,981,528New position
RD
Ray Dalio
Bridgewater Associates
0.03%$7,928,825▲ +125.9%
IE
Israel Englander
Millennium Management
0.03%$86,334,988▲ +26.5%
PF
Pale Fire Capital
Pale Fire Capital SE
0.03%$374,160New position
Ns
Norský státní fond
Norges Bank
0.02%$227,160,019New position
Šn
Švýcarská národní banka
Swiss National Bank
0.02%$32,645,460unchanged
BN
Bill Nygren
Oakmark (Harris Associates)
0%$448,992unchanged

Frequently asked questions

How much is Tenet Healthcare Corp (THC) stock?

Tenet Healthcare Corp shares trade at $262.05, -2.57% over the last trading day. The price is delayed.

What is the market cap of Tenet Healthcare Corp?

The market cap of Tenet Healthcare Corp is about $21.1B and its price-to-earnings ratio (P/E) is 10.1.

Which big investors hold Tenet Healthcare Corp?

According to the latest 13F filings, 13 of 87 tracked investors hold Tenet Healthcare Corp, for example Larry Robbins, David Einhorn, Louis Bacon.

When will Tenet Healthcare Corp report its next results?

The next earnings report of Tenet Healthcare Corp is expected on 29 Oct 2026.

Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.

© 2026 FinBoss.io. All rights reserved.

How we make moneyTerms of usePrivacy policyCookie policy

Disclaimer: the information on this site is for general information only and is not investment or financial advice. Investing involves risk, and cryptocurrencies are especially volatile. Past performance does not guarantee future results. Some links are affiliate links and are marked as ads.

✓
  • ✓The stock is cheaper: you pay 10.1 USD for 1 USD of annual earnings.
  • What to watch
    • Nothing notable from the statements.

    The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.

    Is the stock expensive?

    Fairly cheap

    For 1 USD of annual earnings you pay 10.1 USD. Based on next year's estimates 12.4 USD.

    P/E
    10.1×
    P/S
    1.0×
    EV/EBITDA
    7.6×

    Is the company growing?

    Growing slowly
    22
    23
    24
    25

    Revenue over 3 years grew 3.6% a year. Last year 6.8%.

    Does it make money?

    Good
    • Cost of sales 18
    • Research 0.0
    • Operations and selling 66.1
    • Taxes and other 9.5
    • Net profit 6.6

    Out of 100 USD of revenue, 6.6 USD is left as net profit.

    Is it financially healthy?

    Mostly
    Cash
    2.2B USD
    Debt
    13.2B USD
    Free CF
    2.2B USD

    It could repay its net debt from free cash flow in 4.9 years.

    Does it pay a dividend?

    No dividend

    The company pays no dividend. It reinvests the money or holds it.

    What do analysts expect?

    Buy
    Average target
    286.41 USD
    Vs price
    +9%

    22 analysts. Their opinion is not a recommendation by FinBoss.io.

    Which big investors hold it?

    13 of 87

    Among the tracked investors, Larry Robbins, David Einhorn, Louis Bacon and others hold the stock according to 13F filings.

    Revenue and net profit (USD B)

    Margins (% of revenue)

    Free cash flow and capex (USD B)

    Cash and debt (USD B)

    Earnings per share (EPS, USD)

    Latest quarters (USD B)

    Ratios

    P/E
    10.1×
    Forward P/E
    12.4×
    P/B
    4.5×
    P/S
    1.0×
    PEG
    1.87
    EV/EBITDA
    7.6×
    Gross margin
    41.7%
    Operating margin
    18.2%
    Net margin
    10.3%
    ROE
    37.3%
    ROA
    8.3%
    Debt / equity
    1.5×
    Current ratio
    1.4×
    Revenue growth
    6.8%
    Earnings growth
    213.4%
    Beta
    1.20
    Dividend
    0.00%
    Payout ratio
    0%